Ahmet Dirican: FDA Approves Encorafenib, Cetuximab and Fluorouracil-Based Chemotherapy for BRAF V600E mCRC
Ahmet Dirican/X

Ahmet Dirican: FDA Approves Encorafenib, Cetuximab and Fluorouracil-Based Chemotherapy for BRAF V600E mCRC

Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:

“FDA grants traditional approval to encorafenib + cetuximab + fluorouracil-based chemotherapy for BRAF V600E metastatic CRC.”

Other articles featuring Ahmet Dirican on OncoDaily